Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.33 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.32 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3499071 | 0.98 | MEN1 (0.36) | MEN1KMT2AACECSNK2A2CSNK2B | |
| SCHEMBL22122291 | 0.83 | RAB9A (0.38) | MAPTTSHRSLC6A1SLC6A13 | |
| SCHEMBL22122289 | 0.83 | RAB9A (0.38) | MAPTTSHRSLC6A1SLC6A13 | |
| SCHEMBL8141548 | 0.79 | CHRM5 (0.30) | CHRM5CHRM3 | |
| SCHEMBL7314915 | 0.79 | ALDH1A1 (0.35) | MEN1KMT2AMAPTTSHR | |
| SCHEMBL761343 | 0.79 | MAPT (0.33) | MAPT | |
| SCHEMBL22636281 | 0.78 | POLB (0.33) | — | |
| SCHEMBL22636279 | 0.78 | POLB (0.33) | — | |
| SCHEMBL1386473 | 0.76 | — | — | |
| SCHEMBL25088955 | 0.76 | TOP2A (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037807-A1 | Pyridine compounds as inhibitors of dipeptidyl peptidase IV | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037807-A1 | Pyridine compounds as inhibitors of dipeptidyl peptidase IV | DPP4, DPP3, PEPD | MEN1 3810/4885KMT2A 1601/4885ACE 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.